Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone

Schizophrenia Research

Volumn 132, Issue 1, 2011, Pages 28-34

  Sliwa, Jennifer Kern ^a   Bossie, Cynthia A ^a   Ma, Yi Wen ^b   Alphs, Larry ^a  

^a LLC   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Atypical antipsychotic; Long acting injectable; Paliperidone palmitate; Risperidone; Schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; FEMALE; GALACTORRHEA; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT CHANGE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 80052636583     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.06.016     Document Type: Article

References (31)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, Text Revision. Fourth Edition.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
3. Boom S., Thyssen A., Crauwels H., Molz K.H., Cleton A., Janssens L., Talluri K., Eerdekens M. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int. J. Clin. Pharmacol. Ther. 2009, 47:606-616.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
5. Canuso C.M., Youssef E.A., Bossie C.A., Turkoz I., Schreiner A., Simpson G.M. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int. Clin. Psychopharmacol. 2008, 23:209-215.
6. Canuso C.M., Grinspan A., Kalali A., Damaraju C.V., Merriman U., Alphs L., Awad A.G. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int. Clin. Psychopharmacol. 2010, 25:155-164.
7. Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract. 2010, 64:216-239.
8. Ereshefsky L., Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry 2003, 64:18-23.
9. Gopal S., Gassmann-Mayer C., Palumbo J., Samtani M.N., Shiwach R., Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr. Med. Res. Opin. 2010, 26:377-387.
10. Gopal S., Hough D.W., Xu H., Lull J.M., Gassmann-Mayer C., Remmerie B.M., Eerdekens M.H., Brown D.W. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int. Clin. Psychopharmacol. 2010, 25:247-256.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology (028 Clinical Global Impressions [CGI]) 1976, 218-222.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised 1976 (Abnormal Involuntary Movement Scale [AIMS]) 1976, 534-537. National Institute of Mental Health, Rockville, MD.
13. Hough D., Gopal S., Vijapurkar U., Lim P., Morozova M., Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2010, 116:107-117.
14. Invega® Sustenna® (paliperidone palmitate) extended-release injectable suspension 2010, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ.
15. Kane J.M., Carcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br. J. Psychiatry 2009, 195:S63-S67.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
17. Kramer M., Litman R., Hough D., Lane R., Lim P., Liu Y., Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int. J. Neuropsychopharmacol. 2010, 13:635-647.
18. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
19. Lindenmayer J.P., Liu-Seifert H., Kulkarni P.M., Kinon B.J., Stauffer V., Edwards S.E., Chen L., Adams D.H., Ascher-Svanum H., Buckley P.F., Citrome L., Volavka J. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J. Clin. Psychiatry 2009, 70:990-996.
20. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58:538-546.
21. McEvoy J.P. Risks versus benefits of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry 2006, 67(suppl 5):15-18.
22. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101:323-329.
23. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 2007, 115:260-267.
24. Novick D., Haro J.M., Suarez D., Perez V., Dittmann R.W., Haddad P.M. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010, 176:109-113.
25. Pandina G.J., Lindenmayer J.P., Lull J., Lim P., Gopal S., Herben V., Kusumakar V., Yuen E., Palumbo J. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J. Clin. Psychopharmacol. 2010, 30:235-244.
26. Risperdal® (risperidone) tablets/oral solution 2010, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ.
27. Samtani M.N., Vermeulen A., Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 2009, 48:585-600.
28. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
29. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70:1-46.
30. Vermeir M., Naessens I., Remmerie B., Mannens G., Hendrickx J., Sterkens P., Talluri K., Boom S., Eerdekens M., Van Osselaer N., Cleton A. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 2008, 36:769-779.
31. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 2004, 55:886-891.